The Conversation (0)
Aldeyra Therapeutics released their financial results for their first quarter of 2017 and provided a corporate update.
Aldeyra Therapeutics (NASDAQ:ALDX) released their financial results for their first quarter of 2017 and provided a corporate update.
As quoted in the press release:
“We are pleased to update our progress with four clinical programs, three of which are now in late-stage development,” commented Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra. “We expect results from our Phase 2b clinical trial in allergic conjunctivitis in June of this year, results from our Phase 2a clinical trial in Dry Eye Syndrome in the third quarter of this year, results from our Phase 3 clinical trial in noninfectious anterior uveitis in the second half of next year, and initial top-line data from our Phase 3 clinical trial in Sjögren-Larsson Syndrome in the second half of next year. With the initiation of a Phase 3 clinical trial in noninfectious anterior uveitis, the advancement of our clinical pipeline across four clinical indications – coupled with the receipt of orphan designation for ichthyosis – highlights the productivity achieved in the first quarter.”
Click here to read the full press release.
Source: www.marketwired.com